Literature DB >> 28526295

Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease.

Ignacio F Mata1, Catherine O Johnson2, James B Leverenz3, Daniel Weintraub4, John Q Trojanowski5, Vivianna M Van Deerlin6, Beate Ritz7, Rebecca Rausch8, Stewart A Factor9, Cathy Wood-Siverio9, Joseph F Quinn10, Kathryn A Chung10, Amie L Peterson-Hiller10, Alberto J Espay11, Fredy J Revilla12, Johnna Devoto11, Dora Yearout1, Shu-Ching Hu1, Brenna A Cholerton13, Thomas J Montine14, Karen L Edwards2, Cyrus P Zabetian15.   

Abstract

Cognitive impairment is a common and disabling problem in Parkinson's disease (PD). Identification of genetic variants that influence the presence or severity of cognitive deficits in PD might provide a clearer understanding of the pathophysiology underlying this important nonmotor feature. We genotyped 1105 PD patients from the PD Cognitive Genetics Consortium for 249,336 variants using the NeuroX array. Participants underwent assessments of learning and memory (Hopkins Verbal Learning Test-Revised [HVLT-R]), working memory/executive function (Letter-Number Sequencing and Trail Making Test [TMT] A and B), language processing (semantic and phonemic verbal fluency), visuospatial abilities (Benton Judgment of Line Orientation [JoLO]), and global cognitive function (Montreal Cognitive Assessment). For common variants, we used linear regression to test for association between genotype and cognitive performance with adjustment for important covariates. Rare variants were analyzed using the optimal unified sequence kernel association test. The significance threshold was defined as a false discovery rate-corrected p-value (PFDR) of 0.05. Eighteen common variants in 13 genomic regions exceeded the significance threshold for one of the cognitive tests. These included GBA rs2230288 (E326K; PFDR = 2.7 × 10-4) for JoLO, PARP4 rs9318600 (PFDR = 0.006), and rs9581094 (PFDR = 0.006) for HVLT-R total recall, and MTCL1 rs34877994 (PFDR = 0.01) for TMT B-A. Analysis of rare variants did not yield any significant gene regions. We have conducted the first large-scale PD cognitive genetics analysis and nominated several new putative susceptibility genes for cognitive impairment in PD. These results will require replication in independent PD cohorts. Published by Elsevier Inc.

Entities:  

Keywords:  Cognitive impairment; Genetics; NeuroX; Parkinson's disease

Mesh:

Substances:

Year:  2017        PMID: 28526295      PMCID: PMC5536182          DOI: 10.1016/j.neurobiolaging.2017.04.009

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  34 in total

Review 1.  Advances in the treatment of cognitive impairment in Parkinson's disease.

Authors:  Jennifer G Goldman; Daniel Weintraub
Journal:  Mov Disord       Date:  2015-08-22       Impact factor: 10.338

2.  GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease.

Authors:  Ignacio F Mata; James B Leverenz; Daniel Weintraub; John Q Trojanowski; Alice Chen-Plotkin; Vivianna M Van Deerlin; Beate Ritz; Rebecca Rausch; Stewart A Factor; Cathy Wood-Siverio; Joseph F Quinn; Kathryn A Chung; Amie L Peterson-Hiller; Jennifer G Goldman; Glenn T Stebbins; Bryan Bernard; Alberto J Espay; Fredy J Revilla; Johnna Devoto; Liana S Rosenthal; Ted M Dawson; Marilyn S Albert; Debby Tsuang; Haley Huston; Dora Yearout; Shu-Ching Hu; Brenna A Cholerton; Thomas J Montine; Karen L Edwards; Cyrus P Zabetian
Journal:  Mov Disord       Date:  2015-08-21       Impact factor: 10.338

3.  Prediction of the coding sequences of unidentified human genes. XI. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.

Authors:  T Nagase; K Ishikawa; M Suyama; R Kikuno; N Miyajima; A Tanaka; H Kotani; N Nomura; O Ohara
Journal:  DNA Res       Date:  1998-10-30       Impact factor: 4.458

4.  Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease.

Authors:  Roy N Alcalay; Helen Mejia-Santana; Anat Mirelman; Rachel Saunders-Pullman; Deborah Raymond; Christina Palmese; Elise Caccappolo; Laurie Ozelius; Avi Orr-Urtreger; Lorraine Clark; Nir Giladi; Susan Bressman; Karen Marder
Journal:  Parkinsonism Relat Disord       Date:  2014-11-20       Impact factor: 4.891

Review 5.  Prefrontal neurons and the genetics of schizophrenia.

Authors:  D R Weinberger; M F Egan; A Bertolino; J H Callicott; V S Mattay; B K Lipska; K F Berman; T E Goldberg
Journal:  Biol Psychiatry       Date:  2001-12-01       Impact factor: 13.382

Review 6.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Authors:  W R Gibb; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

Review 7.  Markers of cognitive decline in PD: The case for heterogeneity.

Authors:  Oury Monchi; Alexandru Hanganu; Pierre Bellec
Journal:  Parkinsonism Relat Disord       Date:  2016-01-07       Impact factor: 4.891

8.  Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management.

Authors:  Joana Meireles; João Massano
Journal:  Front Neurol       Date:  2012-05-25       Impact factor: 4.003

9.  Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease.

Authors:  Mike A Nalls; Nathan Pankratz; Christina M Lill; Chuong B Do; Dena G Hernandez; Mohamad Saad; Anita L DeStefano; Eleanna Kara; Jose Bras; Manu Sharma; Claudia Schulte; Margaux F Keller; Sampath Arepalli; Christopher Letson; Connor Edsall; Hreinn Stefansson; Xinmin Liu; Hannah Pliner; Joseph H Lee; Rong Cheng; M Arfan Ikram; John P A Ioannidis; Georgios M Hadjigeorgiou; Joshua C Bis; Maria Martinez; Joel S Perlmutter; Alison Goate; Karen Marder; Brian Fiske; Margaret Sutherland; Georgia Xiromerisiou; Richard H Myers; Lorraine N Clark; Kari Stefansson; John A Hardy; Peter Heutink; Honglei Chen; Nicholas W Wood; Henry Houlden; Haydeh Payami; Alexis Brice; William K Scott; Thomas Gasser; Lars Bertram; Nicholas Eriksson; Tatiana Foroud; Andrew B Singleton
Journal:  Nat Genet       Date:  2014-07-27       Impact factor: 38.330

10.  Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies.

Authors:  Jose Bras; Rita Guerreiro; Lee Darwent; Laura Parkkinen; Olaf Ansorge; Valentina Escott-Price; Dena G Hernandez; Michael A Nalls; Lorraine N Clark; Lawrence S Honig; Karen Marder; Wiesje M Van Der Flier; Afina Lemstra; Philip Scheltens; Ekaterina Rogaeva; Peter St George-Hyslop; Elisabet Londos; Henrik Zetterberg; Sara Ortega-Cubero; Pau Pastor; Tanis J Ferman; Neill R Graff-Radford; Owen A Ross; Imelda Barber; Anne Braae; Kristelle Brown; Kevin Morgan; Walter Maetzler; Daniela Berg; Claire Troakes; Safa Al-Sarraj; Tammaryn Lashley; Yaroslau Compta; Tamas Revesz; Andrew Lees; Nigel Cairns; Glenda M Halliday; David Mann; Stuart Pickering-Brown; Dennis W Dickson; Andrew Singleton; John Hardy
Journal:  Hum Mol Genet       Date:  2014-06-27       Impact factor: 6.150

View more
  13 in total

Review 1.  Cognitive and behavioral disorders in Parkinson's disease: an update. I: cognitive impairments.

Authors:  Costanza Papagno; Luigi Trojano
Journal:  Neurol Sci       Date:  2017-10-17       Impact factor: 3.307

2.  Longitudinal Epigenome-Wide Methylation Study of Cognitive Decline and Motor Progression in Parkinson's Disease.

Authors:  Yu-Hsuan Chuang; Ake T Lu; Kimberly C Paul; Aline D Folle; Jeff M Bronstein; Yvette Bordelon; Steve Horvath; Beate Ritz
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568

Review 3.  The Neuropsychiatry of Parkinson Disease: A Perfect Storm.

Authors:  Daniel Weintraub; Eugenia Mamikonyan
Journal:  Am J Geriatr Psychiatry       Date:  2019-03-09       Impact factor: 4.105

4.  Association of Polygenic Risk Score With Cognitive Decline and Motor Progression in Parkinson Disease.

Authors:  Kimberly C Paul; Jessica Schulz; Jeff M Bronstein; Christina M Lill; Beate R Ritz
Journal:  JAMA Neurol       Date:  2018-03-01       Impact factor: 18.302

5.  Common X-Chromosome Variants Are Associated with Parkinson Disease Risk.

Authors:  Yann Le Guen; Valerio Napolioni; Michael E Belloy; Eric Yu; Lynne Krohn; Jennifer A Ruskey; Ziv Gan-Or; Gabriel Kennedy; Sarah J Eger; Michael D Greicius
Journal:  Ann Neurol       Date:  2021-03-06       Impact factor: 11.274

6.  The Missing Heritability of Sporadic Frontotemporal Dementia: New Insights from Rare Variants in Neurodegenerative Candidate Genes.

Authors:  Miriam Ciani; Cristian Bonvicini; Catia Scassellati; Matteo Carrara; Carlo Maj; Silvia Fostinelli; Giuliano Binetti; Roberta Ghidoni; Luisa Benussi
Journal:  Int J Mol Sci       Date:  2019-08-10       Impact factor: 5.923

7.  Multivariate prediction of dementia in Parkinson's disease.

Authors:  Thanaphong Phongpreecha; Brenna Cholerton; Ignacio F Mata; Cyrus P Zabetian; Kathleen L Poston; Nima Aghaeepour; Lu Tian; Joseph F Quinn; Kathryn A Chung; Amie L Hiller; Shu-Ching Hu; Karen L Edwards; Thomas J Montine
Journal:  NPJ Parkinsons Dis       Date:  2020-08-25

8.  Pleiotropic Effects of Variants in Dementia Genes in Parkinson Disease.

Authors:  Laura Ibanez; Umber Dube; Albert A Davis; Maria V Fernandez; John Budde; Breanna Cooper; Monica Diez-Fairen; Sara Ortega-Cubero; Pau Pastor; Joel S Perlmutter; Carlos Cruchaga; Bruno A Benitez
Journal:  Front Neurosci       Date:  2018-04-10       Impact factor: 4.677

9.  Sensorimotor Inhibition and Mobility in Genetic Subgroups of Parkinson's Disease.

Authors:  Douglas N Martini; Rosie Morris; Valerie E Kelly; Amie Hiller; Kathryn A Chung; Shu-Ching Hu; Cyrus P Zabetian; John Oakley; Kathleen Poston; Ignacio F Mata; Karen L Edwards; Jodi A Lapidus; Thomas J Grabowski; Thomas J Montine; Joseph F Quinn; Fay Horak
Journal:  Front Neurol       Date:  2020-09-04       Impact factor: 4.003

10.  Dopamine effects on memory load and distraction during visuospatial working memory in cognitively normal Parkinson's disease.

Authors:  Ece Bayram; Irene Litvan; Brenton A Wright; Cailey Grembowski; Qian Shen; Deborah L Harrington
Journal:  Neuropsychol Dev Cogn B Aging Neuropsychol Cogn       Date:  2020-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.